Trial Profile
A pivotal registration study of CAVATAK / ipilimumab combination in patients who have failed prior checkpoint therapy.
Status:
Planning
Phase of Trial:
Phase III
Latest Information Update: 11 Apr 2017
Price :
$35
*
At a glance
- Drugs Gebasaxturev (Primary) ; Ipilimumab (Primary)
- Indications Malignant melanoma
- Focus Registrational; Therapeutic Use
- Sponsors Viralytics
- 11 Apr 2017 New trial record